Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
Copyright © 2023 Elsevier Inc. All rights reserved..
INTRODUCTION: The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small-cell lung cancer (NSCLC). We aimed to assess baseline LIPI correlation with durvalumab consolidation outcomes in the locally advanced setting.
MATERIAL AND METHODS: Multicentre retrospective study (330 patients) with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and December 2020; 65 patients treated with chemo-radiotherapy only. Baseline LIPI characterized 3 groups: good (dNLR≤3+LDH≤ULN), intermediate (dNLR>3/LDH>ULN) and poor (dNLR>3+LDH>ULN). Primary endpoint was overall survival (OS).
RESULTS: In the durvalumab cohort, median age was 67 years, 95% smokers, 98% with a performance status of 0-1; 60% had nonsquamous histology and 16% a PD-L1 expression <1%. Radiotherapy was delivered concurrently in 81%. LIPI was evaluable in 216 patients: 66% good, 31% intermediate, 3% poor. LIPI significantly correlated with median OS (median follow-up: 19 months): 18.1 months vs. 47.0 months vs. not reached in poor, intermediate and good LIPI groups, respectively (P = .03). A trend between objective response rate and LIPI groups was observed: 0% vs. 41% vs. 45%, respectively (P = .05). The pooled intermediate/poor LIPI group was associated with shorter OS (HR 1.97; P = .03) and higher risk of progressive disease (OR 2.68; P = .047). Survivals and response were not influenced in the control cohort.
CONCLUSION: Baseline LIPI correlated with outcomes in patients with locally advanced NSCLC treated with durvalumab consolidation, but not in those who only received chemo-radiotherapy, providing further evidence of its prognostic and potential predictive role of ICI benefit in NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Clinical lung cancer - (2023) vom: 22. Nov. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Consolidation |
|---|
| Anmerkungen: |
Date Revised 17.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.cllc.2023.11.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365958522 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365958522 | ||
| 003 | DE-627 | ||
| 005 | 20231227134208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cllc.2023.11.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM365958522 | ||
| 035 | |a (NLM)38105153 | ||
| 035 | |a (PII)S1525-7304(23)00242-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Riudavets, Mariona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small-cell lung cancer (NSCLC). We aimed to assess baseline LIPI correlation with durvalumab consolidation outcomes in the locally advanced setting | ||
| 520 | |a MATERIAL AND METHODS: Multicentre retrospective study (330 patients) with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and December 2020; 65 patients treated with chemo-radiotherapy only. Baseline LIPI characterized 3 groups: good (dNLR≤3+LDH≤ULN), intermediate (dNLR>3/LDH>ULN) and poor (dNLR>3+LDH>ULN). Primary endpoint was overall survival (OS) | ||
| 520 | |a RESULTS: In the durvalumab cohort, median age was 67 years, 95% smokers, 98% with a performance status of 0-1; 60% had nonsquamous histology and 16% a PD-L1 expression <1%. Radiotherapy was delivered concurrently in 81%. LIPI was evaluable in 216 patients: 66% good, 31% intermediate, 3% poor. LIPI significantly correlated with median OS (median follow-up: 19 months): 18.1 months vs. 47.0 months vs. not reached in poor, intermediate and good LIPI groups, respectively (P = .03). A trend between objective response rate and LIPI groups was observed: 0% vs. 41% vs. 45%, respectively (P = .05). The pooled intermediate/poor LIPI group was associated with shorter OS (HR 1.97; P = .03) and higher risk of progressive disease (OR 2.68; P = .047). Survivals and response were not influenced in the control cohort | ||
| 520 | |a CONCLUSION: Baseline LIPI correlated with outcomes in patients with locally advanced NSCLC treated with durvalumab consolidation, but not in those who only received chemo-radiotherapy, providing further evidence of its prognostic and potential predictive role of ICI benefit in NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Consolidation | |
| 650 | 4 | |a Durvalumab | |
| 650 | 4 | |a Host-related biomarkers | |
| 650 | 4 | |a LIPI | |
| 650 | 4 | |a Stage III | |
| 700 | 1 | |a Auclin, Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Mosteiro, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Dempsey, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Majem, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Prelaj, Arsela |e verfasserin |4 aut | |
| 700 | 1 | |a López-Castro, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch-Barrera, Joaquim |e verfasserin |4 aut | |
| 700 | 1 | |a Pilotto, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Escalera, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Tagliamento, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Mosquera, Joaquin |e verfasserin |4 aut | |
| 700 | 1 | |a Zalcman, Gérard |e verfasserin |4 aut | |
| 700 | 1 | |a Aboubakar Nana, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Ponce, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Albarrán-Artahona, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Dal Maso, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Spotti, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Mielgo, Xabier |e verfasserin |4 aut | |
| 700 | 1 | |a Mussat, Elodie |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Roxana |e verfasserin |4 aut | |
| 700 | 1 | |a Benítez, Jose-Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Lupinacci, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Duchemann, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a De Giglio, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Blaquier, Juan Bautista |e verfasserin |4 aut | |
| 700 | 1 | |a Audigier-Valette, Clarisse |e verfasserin |4 aut | |
| 700 | 1 | |a Scheffler, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Nadal, Ernest |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Gilberto |e verfasserin |4 aut | |
| 700 | 1 | |a Signorelli, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Campelo, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Menis, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Bluthgen, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Campayo, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Recondo, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Besse, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Mezquita, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Planchard, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lung cancer |d 1999 |g (2023) vom: 22. Nov. |w (DE-627)NLM143155229 |x 1938-0690 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:22 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cllc.2023.11.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 22 |c 11 | ||